Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958302 | 0.89 | HTR2A (0.44) | HTR2AHTR2CHTR2BHTR1ADRD3 | |
| SCHEMBL18527205 | 0.74 | HTR2A (0.36) | HTR2AHTR2CHTR2BMAOAMAOB | |
| SCHEMBL29395407 | 0.74 | HTR2A (0.44) | HTR2AHTR2CHTR2BHTR1ADRD3 | |
| SCHEMBL18527219 | 0.69 | HTR2A (0.46) | HTR2AHTR2CHTR2BHTR1ADRD3 | |
| SCHEMBL19869345 | 0.68 | CYP2A6 (0.30) | — | |
| SCHEMBL4429415 | 0.68 | PAX8 (0.48) | HTR2AHTR2CHTR2BMAOAMAOB | |
| SCHEMBL13983903 | 0.67 | HTR2C (0.66) | HTR2AHTR2CHTR2BPARP1HTR1A | |
| SCHEMBL26064999 | 0.66 | HTR2A (0.36) | HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL26065397 | 0.66 | HTR1A (0.32) | HTR1ADRD3 | |
| SCHEMBL30956292 | 0.66 | HTR2A (0.39) | HTR2AHTR2CHTR2BMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20100120760-A1 | BENZOFURAN-CARBOXAMIDE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANG (IT) | 2010-05-13 | — | — | US | disclosed |
| EP-2146999-A1 | BENZOFURAN- CARBOXAMIDE DERIVATIVES AS ANTIVIRAL AGENTS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125874-A1 | BENZOFURAN- CARBOXAMIDE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | HTR2A 189/4885HTR2C 215/4885HTR2B 549/4885 |
| US-20100120760-A1 | BENZOFURAN-CARBOXAMIDE DERIVATIVES AS ANTIVIRAL AGENTS | ZC3HAV1, EIF2AK2, GTF3C1 | HTR2A 4666/4885HTR2C 4068/4885HTR2B 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.